Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2023-03-30 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于2022年度审计费用的确认及续聘2023年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the confirmation of audit fees for the fiscal year 2022 and the reappointment of the audit firm for 2023. It details the audit firm's credentials, audit fees, and the approval process by the board and shareholders. It does not contain the audit report itself or detailed financial statements but rather information about the audit engagement and related approvals. This fits the category of Audit Report / Information (AR), which includes standalone audit reports, applied accounting principles, and related audit information excluding full annual reports. The document length is 3283 characters, which is relatively short but contains substantive information about audit fees and auditor reappointment, not just a brief announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2022
2023-03-30 Chinese
未来三年（2023年-2025年）股东分红回报规划
Notice of Dividend Amount Classification · 95% confidence The document is a detailed announcement of a company's shareholder dividend return plan for the next three years (2023-2025). It outlines principles, conditions, and mechanisms for dividend distribution, referencing regulatory guidelines from the China Securities Regulatory Commission. The document is a formal announcement of a policy plan rather than a financial report or earnings release. It does not contain financial statements or audit opinions, nor is it a transcript or management discussion. It is not a report publication announcement since it contains substantive content about the dividend policy itself. The content fits best with a Notice of Dividend Amount (DIV) category, as it relates to dividend distribution plans and shareholder returns.
2023-03-30 Chinese
中航证券有限公司关于公司增加2023年度日常关联交易预计的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (中航证券有限公司) regarding the increase in the estimated amount of daily related-party transactions for the year 2023 by 健帆生物科技集团股份有限公司. It includes descriptions of the related parties, transaction categories, amounts, pricing principles, and independent directors' opinions. The document is focused on the review and approval of related-party transactions rather than presenting financial statements or audit results. It is not an annual report, audit report, earnings release, or any other financial report type. It is a regulatory compliance-related filing concerning related-party transactions and their approval process, which fits best under Regulatory Filings (RNS). The document length is 4443 characters, which is relatively short but contains substantive content rather than just an announcement. Therefore, the classification is RNS with high confidence.
2023-03-30 Chinese
独立董事提名人声明（二）
Board/Management Information Classification · 100% confidence The document is a formal statement nominating an independent director candidate for the company's board. It includes detailed declarations about the nominee's qualifications, compliance with regulatory requirements, and independence criteria. There is no financial data, no report of financial performance, no voting results, and no mention of a meeting or shareholder vote outcome. The content is focused on board/management information, specifically the nomination of a board member. The document length is 4480 characters, which is relatively short but contains substantive content about management nomination rather than a mere announcement. Therefore, the appropriate classification is Board/Management Information (MANG).
2023-03-30 Chinese
国浩律师（深圳）事务所关于公司回购注销部分限制性股票的法律意见书
Transaction in Own Shares Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the repurchase and cancellation of certain restricted shares of a company. It details the legal basis, approvals, authorizations, and specific circumstances of the share repurchase and cancellation under a stock incentive plan. The document does not contain financial statements or quarterly/yearly financial results, nor is it a regulatory announcement or a report publication notice. It is a legal opinion related to a capital transaction involving share repurchase and cancellation. Therefore, the most appropriate classification is 'Transaction in Own Shares' (POS), which covers reports of the company buying back or selling its own shares (share repurchase/issuance). The document length (6060 characters) and content support this classification with high confidence.
2023-03-30 Chinese
关于2022年年度报告披露的提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (467 characters) regarding the disclosure of the company's 2022 Annual Report. It states that the full annual report and summary will be disclosed on a specific date on a regulatory website. There is no actual financial data or detailed report content included in this text. According to the 'MENU VS MEAL' rule, this is an announcement about the publication of the annual report, not the report itself. Therefore, the correct classification is Report Publication Announcement (RPA).
2023-03-30 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.